• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Weather-induced FDA delay hits Staar Surgical’s bottom line

Weather-induced FDA delay hits Staar Surgical’s bottom line

May 1, 2014 By Arezu Sarvestani

Weather-induced FDA delay hits Staar Surgical's bottom line

California-based STAAR Surgical (NSDQ:STAA) swung hard to a 1st-quarter loss after storm-related regulatory delays cost the company its bottom line.

Staar went from a 1¢ per diluted share profit during this time last year to a 4¢ loss. Excluding special charges, its earnings would have amounted to a profit of 4¢ per share, beating Wall Street’s estimates.

The FDA in February postponed an Advisory Panel meeting slated to review Staar’s Toric ICL intraocular implant, costing the medical device maker double what it had expected to pay in regulatory costs.

"Our expenses related to the FDA Panel Advisory meeting were expected to be higher during the quarter as a result of the postponement of the February 14th panel meeting due to weather and the re-scheduling to March 14th," president & CEO Barry Caldwell said in prepared remarks. "These costs associated with the Advisory meeting were nearly double our original forecast and led to the GAAP net loss for the quarter."

Staar has since had its day with the FDA, during which the agency’s advisors recommended approval for the Toric ICL, but the delay cost the company $1 million.

In total Staar Surgical reported losses of $1.4 million, or 4¢ per share, on sales of $20.2 million during the 3 months ended April 4. That compared with profits of $471 million, or 1¢ per share, on sales of $18 million during the same period last year. Total FDA panel expenses came to about $1.4 million for the quarter, according to a financial report.

STAA shares dropped hard in yesterday’s trading following release of the financial news. Shares closed at $17.01, down 9.3% on the day.

Filed Under: Food & Drug Administration (FDA), MassDevice Earnings Roundup, News Well, Optical/Ophthalmic, Wall Street Beat Tagged With: 2014, Q1, Regulatory, STAAR Surgical Co

More recent news

  • Medtronic escapes $106.5M payment in Colibri TAVR patent suit after court overturns jury verdict
  • RadNet closes iCAD acquisition, expands AI breast‑imaging portfolio
  • Hyperfine reports first commercial sales of next-gen AI-powered Swoop
  • Stereotaxis announces $12.5M offering
  • Nuwellis ends clinical trial of its ultrafiltration tech for heart failure

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy